FDA
-
-
-
-
-
-
-
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
-
-
-
-
-
-
-
TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
-
-
-
-
-
-
-
Gozellix Receives Permanent HCPCS Code
-
-
-
-
-
-
-
Telix Reports US$186M Q1 Revenue, Up 62% YOY
-
-
-
-
-
-
-
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
-
-
-
-
-
-
-
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
-
-
-
-
-
-
-
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

